BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 9445185)

  • 1. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
    Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
    Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
    Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
    Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.
    Baka S; Agelaki S; Kotsakis A; Veslemes M; Papakotoulas P; Agelidou M; Agelidou A; Tsaroucha E; Pavlakou G; Gerogianni A; Androulakis N; Vamvakas L; Kalbakis K; Mavroudis D; Georgoulias V
    Anticancer Res; 2010 Jul; 30(7):3031-8. PubMed ID: 20683051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxol (paclitaxel) in the treatment of lung cancer: the Eastern Cooperative Oncology Group experience.
    Johnson DH; Chang AY; Ettinger DS
    Ann Oncol; 1994; 5 Suppl 6():S45-50. PubMed ID: 7865434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.
    Crino L; Tonato M; Darwish S; Meacci ML; Corgna E; Di Costanzo F; Buzzi F; Fornari G; Santi E; Ballatori E
    Cancer Chemother Pharmacol; 1990; 26(1):52-6. PubMed ID: 2157554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial.
    Luedke DW; Einhorn L; Omura GA; Sarma PR; Bartolucci AA; Birch R; Greco FA
    J Clin Oncol; 1990 May; 8(5):886-91. PubMed ID: 2159054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.
    Shirinian M; Lee JS; Dhingra HH; Greenberg J; Hong WK
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):49-53. PubMed ID: 1329212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium.
    Klastersky J; Sculier JP; Bureau G; Libert P; Ravez P; Vandermoten G; Thiriaux J; Lecomte J; Cordier R; Dabouis G
    J Clin Oncol; 1989 Aug; 7(8):1087-92. PubMed ID: 2547028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung.
    Schiller JH; Storer B; Dreicer R; Rosenquist D; Frontiera M; Carbone PP
    J Natl Cancer Inst; 1989 Nov; 81(22):1739-43. PubMed ID: 2553993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.
    Shepherd FA; Evans WK; Goss PE; Latreille J; Logan D; Maroun J; Stewart D; Warner E; Paul K
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):54-8. PubMed ID: 1329213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, adriamycin, methotrexate, and procarbazine versus cisplatin and etoposide. A randomized study.
    Veronesi A; Magri MD; Tirelli U; Carbone A; Mazza F; Franceschi S; Talamini R; Ardizzoni A; Canobbio L; Rosso R
    Am J Clin Oncol; 1988 Oct; 11(5):566-71. PubMed ID: 2845769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer.
    Splinter T; Kok T; Kho S; Lameris H; ten Kate F; Dalesio O; Dolman B; Palmen F; Bouvy J; Burghouts J
    Semin Oncol; 1986 Sep; 13(3 Suppl 3):97-103. PubMed ID: 3020707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer.
    Cellerino R; Tummarello D; Guidi F; Isidori P; Raspugli M; Biscottini B; Fatati G
    J Clin Oncol; 1991 Aug; 9(8):1453-61. PubMed ID: 1649267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results.
    Chang AY; Kim K; Glick J; Anderson T; Karp D; Johnson D
    J Natl Cancer Inst; 1993 Mar; 85(5):388-94. PubMed ID: 8094467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum/oral etoposide therapy in non-small cell lung cancer.
    Furuse K
    Oncology; 1992; 49 Suppl 1():63-9; discussion 70. PubMed ID: 1323814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.
    Faylona EA; Loehrer PJ; Ansari R; Sandler AB; Gonin R; Einhorn LH
    J Clin Oncol; 1995 May; 13(5):1209-14. PubMed ID: 7738623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma.
    Fossella FV; Winn RJ; Holoye PY; Hallinan B; Raber MN; Hoelzer K; Young JA; Readling J; Bowers B; Hong WK
    Invest New Drugs; 1992 Nov; 10(4):331-5. PubMed ID: 1336771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer.
    Johnson DH; Ruckdeschel JC; Keller JH; Lyman GH; Kallas GJ; Macdonald J; DeConti RC; Lee J; Ringenberg QS; Patterson WP
    Cancer; 1991 Jan; 67(1 Suppl):245-9. PubMed ID: 1845847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.